bausch health companies inc glp-1 receptor agonist medications Glucagon-like Peptide-1 agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence GLP-1 Receptor Agonists and DR

Nausea remains its most common side effect at approximately 40% of patients, though this typically attenuates after the first dose

The results of a meta-analysis indicate that GLP-1RAs can reduce major adverse cardiovascular events (MACE) such as cardiovascular death, stroke, or myocardial infarction, as well as hospital admissions for heart failure and all-cause mortality, in patients with T2D [44]

Obesity as a Public Health Crisis and Contemporary Therapies Between 2021 and 2023, the prevalence of obesity, defined as a body-mass index (BMI, weight in kilograms divided by square of height in meters) 30, in adults in the United States increased to 40.3%, with no significant differences between men and women [6]

Structural insights into the activation of GLP-1R by a small molecule agonist

Abul-HusnNSChengXLiAHXinYSchurmannCStevisPet al